Subgroup analysis revealed a significant interaction by sex in the association between treatment regimen and LCX FAI.<h4>Conclusion</h4>The combined use of SGLT-2 inhibitors and GLP-1RAs may be associated with a decrease in the peri-coronary FAI in patients with T2DM, suggesting a potential role in reducing coronary inflammation. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.